Preliminary Q1 2026 Results: Operating Profit Surges 134%, Net Income Up 158.6%
-
Revenue 14,597 million KRW (YoY +30.0%), operating profit 3,187 million KRW (YoY +134.0%), net income 5,352 million KRW (YoY +158.6%)
-
Sequential revenue slightly decreased -0.2%, but operating profit +4.3% and net income +21.8%
-
Net income attributable to owners of parent 5,352 million KRW (sequential +21.8%)
-
These figures are preliminary and subject to change after external audit review
KOSDAQ Filing Information
-
Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
-
Company: CELL BIOTECH (049960)
-
Submission: CELL BIOTECH CO., LTD.
-
Receipt: 05-08-2026
-
Under KRX KOSDAQ Market Division